journal
MENU ▼
Read by QxMD icon Read
search

Clinical Cancer Research: An Official Journal of the American Association for Cancer Research

journal
https://www.readbyqxmd.com/read/30242024/cdk4-6-inhibitor-as-a-novel-therapeutic-approach-for-advanced-bladder-cancer-independently-of-rb1-status
#1
Carolina Rubio, Mónica Martínez-Fernández, Cristina Segovia, Iris Lodewijk, Cristian Suarez-Cabrera, Carmen Segrelles, Fernando López-Calderón, Ester Munera-Maravilla, Mirentxu Santos, Alejandra Bernardini, Ramon Garcia-Escudero, Corina Lorz, Maria Jose Gomez-Rodriguez, Guillermo De Velasco, Irene Otero Blas, Felipe Villacampa, Felix Guerrero-Ramos, Sergio Ruiz, Federico de la Rosa, Sara Domínguez-Rodríguez, Francisco X Real, Nuria Malats, Daniel Castellano, Marta Dueñas, Jesus M Paramio
PURPOSE: Bladder cancer (BC) is a clinical and social problem due to its high incidence and recurrence rates. It frequently appears in elderly patients showing other medical comorbidities that hamper the use of standard chemotherapy. We evaluated the activity of CDK4/6 inhibitor as a new therapy for patients unfit for cisplatin (CDDP). EXPERIMENTAL DESIGN: BC cell lines were tested for in vitro sensitivity to CDK4/6 inhibition. A novel metastatic BC mouse model was developed and used to test its in vivo activity...
September 21, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30242023/multi-modal-meta-analysis-of-1494-hepatocellular-carcinoma-samples-reveals-significant-impact-of-consensus-driver-genes-on-phenotypes
#2
Kumardeep Chaudhary, Olivier B Poirion, Liangqun Lu, Sijia Huang, Travers Ching, Lana X Garmire
Although driver genes in hepatocellular carcinoma (HCC) have been investigated in various previous genetic studies, prevalence of key driver genes among heterogeneous populations is unknown. Moreover, the phenotypic associations of these driver genes are poorly understood. This report aims to reveal the phenotypic impacts of a group of consensus driver genes in HCC. We used MutSigCV and OncodriveFM modules implemented in the IntOGen pipeline to identify consensus driver genes across six HCC cohorts comprising 1,494 samples in total...
September 21, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30242022/immunotherapy-targeting-hpv-16-18-generates-potent-immune-responses-in-hpv-associated-head-and-neck-cancer
#3
Charu Aggarwal, Roger B Cohen, Matthew P Morrow, Kimberly A Kraynak, Albert J Sylvester, Dawson M Knoblock, Joshua Bauml, Gregory S Weinstein, Alexander Lin, Jean Boyer, Lindsay Sakata, Sophie Tan, Aubrey Anton, Kelsie Dickerson, Drishty Mangrolia, Russell Vang, Michael Dallas, Sandra Oyola, Susan Duff, Mark T Esser, Rakesh Kumar, David B Weiner, Ildiko Csiki, Mark Bagarazzi
PURPOSE: Clinical responses with programmed death (PD-1) receptor directed antibodies occur in about 20% of patients with advanced head and neck squamous cell cancer (HNSCCa). Viral neoantigens, such as the E6/E7 proteins of HPV16/18 are attractive targets for therapeutic immunization, and offer an immune activation strategy that may be complementary to PD-1 inhibition. EXPERIMENTAL DESIGN: We report Phase Ib/II safety, tolerability and immunogenicity results of immunotherapy with MEDI0457 (DNA immunotherapy targeting HPV16/18 E6/E7 with IL-12 encoding plasmids) delivered by electroporation with CELLECTRA® constant current device...
September 21, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30232225/activated-natural-killer-cells-in-combination-with-anti-gd2-antibody-dinutuximab-improve-survival-of-mice-after-surgical-resection-of-primary-neuroblastoma
#4
Wesley E Barry, Jeremy R Jackson, Grace E Asuelime, Hong-Wei Wu, Jianping Sun, Zesheng Wan, Jemily Malvar, Michael A Sheard, Larry Wang, Robert C Seeger, Eugene S Kim
PURPOSE: Immunotherapy of neuroblastoma that remains after myeloablative chemotherapy with anti-GD2 antibody dinutuximab has increased the two-year event-free and overall survival of high-risk neuroblastoma patients; however, 40% of patients develop recurrent disease during or after this treatment. To determine the potential of such antibody-based immunotherapy earlier in treatment, a mouse model was developed in which surgical resection of the primary tumor was followed by therapy of residual disease with dinutuximab combined with ex vivo -activated human natural killer (aNK) cells...
September 19, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30232224/a-phase-ii-trial-of-the-aurora-kinase-a-inhibitor-alisertib-for-patients-with-castration-resistant-and-neuroendocrine-prostate-cancer-efficacy-and-biomarkers
#5
Himisha Beltran, Clara Oromendia, Daniel C Danila, Bruce Montgomery, Christopher Hoimes, Russell Z Szmulewitz, Ulka Vaishampayan, Andrew J Armstrong, Mark Stein, Jacek Pinski, Juan Miguel Mosquera, Verena Sailer, Rohan Bareja, Alessandro Romanel, Naveen Gumpeni, Andrea Sboner, Etienne Dardenne, Loredana Puca, Davide Prandi, Mark A Rubin, Howard I Scher, David S Rickman, Francesca Demichelis, David M Nanus, Karla V Ballman, Scott T Tagawa
BACKGROUND: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression. Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibiting N-myc signaling, and suppressing tumor growth. EXPERIMENTAL DESIGN: Sixty men were treated with alisertib50mg twice daily for 7 days every 21-days. Eligibility included metastatic prostate cancer and at least one: small cell neuroendocrine morphology; 50% neuroendocrine marker expression; new liver metastases without PSA progression; elevated serum neuroendocrine markers...
September 19, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30228210/landscape-of-egfr-dependent-and-independent-resistance-mechanisms-to-osimertinib-and-continuation-therapy-post-progression-in-egfr-mutant-nsclc
#6
Xiuning Le, Sonam Puri, Marcelo V Negrao, Monique Nilsson, Jacqulyne P Robichaux, Theresa A Boyle, James Kevin Hicks, Katherine Lovinger, Emily B Roarty, Waree Rinsurongkawong, Ming Tang, Huiying Sun, Yasir Y Elamin, Lara Lacerda, Jeff Lewis, J Jack Lee, Jack A Roth, Stephen G Swisher, Jianjun Zhang, William N William, Bonnie S Glisson, Vassiliki A Papadimitrakopoulou, Jhanelle E Gray, John V Heymach
PURPOSE: Osimertinib was initially approved for T790M positive NSCLC and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described. EXPERIMENTAL DESIGN: Using cohorts from MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center Lung Cancer databases, we collected clinical data for patients treated with osimertinib. Molecular profiling analysis was performed at the time of progression in a subset of the patients...
September 18, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30228209/functional-silencing-of-hsd17b2-in-prostate-cancer-promotes-disease-progression
#7
Xiaomei Gao, Charles Dai, Shengsong Huang, Jingjie Tang, Guoyuan Chen, Jianneng Li, Ziqi Zhu, Xuyou Zhu, Shuirong Zhou, Yuanyuan Gao, Zemin Hou, Zijun Fang, Chengdang Xu, Jianyang Wang, Denglong Wu, Nima Sharifi, Zhenfei Li
PURPOSE: Steroidogenic enzymes are essential for prostate cancer development. Enzymes inactivating potent androgens were not investigated thoroughly, which leads to limited interfere strategies for prostate cancer therapy. Here we characterized the clinical relevance, significance and regulation mechanism of enzyme HSD17B2 in prostate cancer development. EXPERIMENTAL DESIGN: HSD17B2 expression was detected with patient specimens and prostate cancer cell lines. Function of HSD17B2 in steroidogenesis, AR signaling and tumor growth was investigated with prostate cancer cell lines and xenograft model...
September 18, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30228208/a-pet-imaging-strategy-for-interrogating-target-engagement-and-oncogene-status-in-pancreatic-cancer
#8
Kelly E Henry, Megan M Dacek, Thomas R Dilling, Jonathan D Caen, Ian L Fox, Michael J Evans, Jason S Lewis
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers with a 5-year survival rate of less than 10%. Physicians often rely on biopsy or CT to guide treatment decisions, but these techniques fail to reliably measure the actions of therapeutic agents in PDAC. KRAS mutations are present in >90% of PDAC and are connected to many signaling pathways through its oncogenic cascade, including extracellular regulated kinase (ERK) and MYC. A key downstream event of MYC is transferrin receptor (TfR), which has been identified as a biomarker for cancer therapeutics and imaging...
September 18, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224345/epigenetic-therapy-with-panobinostat-combined-with-bicalutamide-re-challenge-in-castration-resistant-prostate-cancer
#9
Anna C Ferrari, Joshi J Alumkal, Mark N Stein, Mary-Ellen Taplin, James S Babb, Ethan S Barnett, Alejandro Gomez-Pinillos, Xiaomei Liu, Dirk F Moore, Robert S DiPaola, Tomasz M Beer
PURPOSE: To assess the action of panobinostat, a histone deacetylase inhibitor (HDACI), in restoring sensitivity to bicalutamide in a castration-resistant prostate cancer (CRPC) model; to assess the efficacy and safety of the panobinostat/bicalutamide combination in CRPC patients resistant to second-line antiandrogen therapy (2nd LAARx). EXPERIMENTAL DESIGN: The CWR22PC xenograft and isogenic cell line were tested for drug interactions on tumor cell growth and androgen receptor (AR), AR-splice variant7 and AR targets...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224344/divergent-biological-response-to-neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer
#10
Roland Seiler, Ewan A Gibb, Natalie Q Wang, Htoo Zarni Oo, Hung-Ming Lam, Kim E Van Kessel, Charlotte S Voskuilen, Brian Winters, Nicholas G Erho, Mandeep M Takhar, James Douglas, Funda Vakar-Lopez, Simon J Crabb, Bas W G van Rhijn, Elisabeth E Fransen van de Putte, Ellen C Zwarthoff, George N Thalmann, Elai Davicioni, Joost L Boormans, Marc Dall'Era, Michiel S van der Heijden, Jonathan L Wright, Peter C Black
PURPOSE: After cisplatin-based neoadjuvant chemotherapy (NAC) 60% of patients with muscle-invasive bladder cancer still have residual invasive disease at radical cystectomy (RC). The NAC-induced biological alterations in these cisplatin-resistant tumors remain largely unstudied. EXPERIMENTAL DESIGN: RC samples were available for gene expression analysis from 133 patients with residual invasive disease after cisplatin-based NAC, of whom 116 had matched pre-NAC samples...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224343/the-anatomical-location-shapes-the-immune-infiltrate-in-tumors-of-same-etiology-and-impacts-survival
#11
Saskia J Santegoets, Vanessa J van Ham, Ilina Ehsan, Pornpimol Charoentong, Chantal L Duurland, Vincent van Unen, Thomas Höllt, Lilly-Ann van der Velden, Sylvia I van Egmond, Kim Kortekaas, Peggy J de Vos van Steenwijk, Mariette Ie van Poelgeest, Marij J P Welters, Sjoerd H van der Burg
PURPOSE: The tumor immune microenvironment determines clinical outcome. Whether the original tissue in which a primary tumor develops influences this microenvironment is not well understood. EXPERIMENTAL DESIGN: We applied high-dimensional single-cell mass cytometry (CyTOF) analysis and functional studies to analyze immune cell populations in human papillomavirus (HPV)-induced primary tumors of the cervix (CxCa) and oropharynx (OPSCC). RESULTS: Despite the same etiology of these tumors, the composition and functionality of their lymphocytic infiltrate substantially differed...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224342/impact-of-braf-mutation-class-on-disease-characteristics-and-clinical-outcomes-in-braf-mutant-lung-cancer
#12
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, Chiara Ambrogio, Lorin A Ferris, Christine Lydon, Tom Nguyen, Nicholas A Jessop, A John Iafrate, Bruce E Johnson, Jochen K Lennerz, Alice T Shaw, Mark M Awad
PURPOSE: BRAF mutations are divided into functional classes based on signaling mechanism and kinase activity: V600-mutant kinase-activating monomers (class I), kinase-activating dimers (class II), and kinase-inactivating heterodimers (class III). The relationship between functional class and disease characteristics in BRAF-mutant non-small cell lung cancer (NSCLC) has not been fully explored. EXPERIMENTAL DESIGN: We performed a retrospective analysis of BRAF-mutant NSCLCs treated at two institutions from 2005-2017 to determine clinicopathologic characteristics, progression-free survival (PFS) on chemotherapy, and overall survival (OS)...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224341/mavericc-a-randomized-biomarker-stratified-phase-2-study-of-mfolfox6-bevacizumab-vs-folfiri-bevacizumab-as-first-line-chemotherapy-in-metastatic-colorectal-cancer
#13
Aparna R Parikh, Fa-Chyi Lee, Linda Yau, Han Koh, James Knost, Edith P Mitchell, Ivan Bosanac, Nicholas Choong, Frank A Scappaticci, Christoph Mancao, Heinz-Josef Lenz
BACKGROUND: MAVERICC compared the efficacy and safety of modified leucovorin/5-fluorouracil/oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus BV (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC). MATERIALS AND METHODS: MAVERICC was a global, randomized, open-label, phase II study. Primary objectives were to assess associations between 1) excision repair cross-complementing 1 (ERCC1) expression with progression-free survival (PFS), and 2) plasma vascular endothelial growth factor A (VEGF-A) with PFS in patients with previously untreated mCRC receiving mFOLFOX6-BV or FOLFIRI-BV...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224340/tracking-cell-transplants-in-femoral-osteonecrosis-with-magnetic-resonance-imaging-a-proof-of-concept-study-in-patients
#14
Ashok Joseph Theruvath, Hossein Nejadnik, Anne Monika Muehe, Felix Gassert, Norman J Lacayo, Stuart B Goodman, Heike E Daldrup-Link
PURPOSE: Osteonecrosis (ON) is a devastating complication of high dose corticosteroid therapy in cancer patients. Core decompression for prevention of bone collapse has been recently combined with the delivery of autologous concentrated bone marrow aspirates. The purpose of our study was to develop an imaging test for the detection of transplanted bone marrow cells in ON lesions. EXPERIMENTAL DESIGN: In a prospective proof-of-concept clinical trial (NCT02893293), we performed serial MR imaging studies of nine hip joints of seven ON patients before and after core decompression...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224339/notch1-represses-mcl-1-levels-in-gsi-resistant-t-all-making-them-susceptible-to-abt-263
#15
Anahita Dastur, AHyun Choi, Carlotta Costa, Xunqin Yin, August F Williams, Joseph D McClanaghan, Max Greenberg, Justine E Roderick, Neha U Patel, Jessica L Boisvert, Ultan McDermott, Mathew J Garnett, Jorge Almenara, Steven Grant, Kathryn Rizzo, Jeffrey A Engelman, Michelle A Kelliher, Anthony C Faber, Cyril H Benes
PURPOSE: Effective targeted therapies are lacking for refractory and relapsed T-cell Acute Lymphoblastic Leukemia (T-ALL). Suppression of the NOTCH pathway using gamma-secretase inhibitors (GSIs) is toxic and clinically not effective. The goal of this study was to identify alternative therapeutic strategies for T-ALL. EXPERIMENTAL DESIGN: We performed a comprehensive analysis of our high throughput drug screen across hundreds of human cell lines including fifteen T-ALL models...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224338/to-cycle-or-fight-cdk-4-6-inhibitors-at-the-crossroads-of-anti-cancer-immunity
#16
Malaka Ameratunga, Emma Kipps, Alicia Fc Okines, Juanita S Lopez
Dysregulation of cell division resulting in aberrant cell proliferation is a key hallmark of cancer, making it a rational and important target for innovative anti-cancer drug development. Three selective CDK4/6 inhibitors are FDA and EMEA approved for hormone receptor positive/HER2 negative advanced breast cancer. A major emerging appreciation is that these inhibitors are not only cytostatic, but also play critical roles in the interaction between tumour cells and the host immune response. However, to trigger an effective immune response, lymphocytes must also proliferate...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30224337/usp7-cooperates-with-notch1-to-drive-the-oncogenic-transcriptional-program-in-t-cell-leukemia
#17
Qi Jin, Carlos A Martinez, Kelly M Arcipowski, Yixing Zhu, Blanca T Gutiérrez-Díaz, Kenneth K Wang, Megan R Johnson, Andrew Volk, Feng Wang, Jian Wu, Charles Grove, Hui Wang, Ivan Sokirniy, Paul M Thomas, Young Ah Goo, Nebiyu A Abshiru, Nobuko Hijiya, Sofie Peirs, Niels Vandamme, Geert Berx, Steven Goossens, Stacy Ann Marshall, Emily J Rendleman, Yoh-Hei Takahashi, Lu Wang, Radhika Rawat, Elizabeth T Bartom, Clayton K Collings, Pieter Van Vlierberghe, Jean-Pierre Bourquin, Beat Bornhauser, Valentina Serafin, Silvia Bresolin, Maddalena Paganin, Benedetta Accordi, Giuseppe Basso, Neil L Kelleher, Joseph Weinstock, Kumar Suresh, John D Crispino, Ali Shilatifard, Alexandros Strikoudis, Christine Mantis, Irawati Kandela, Stephen Kelly, Beatrix Ueberheide, Panagiotis Ntziachristos
PURPOSE: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease, affecting children and adults. Chemotherapy treatments show high response rates but have debilitating effects and carry risk of relapse. Previous work implicated NOTCH1 and other oncogenes. However, direct inhibition of these pathways affects healthy tissues and cancer alike. Our goal in this work has been to identify enzymes active in T-ALL whose activity could be targeted for therapeutic purposes. EXPERIMENTAL DESIGN: To identify and characterize new NOTCH1 druggable partners in T-ALL, we coupled studies of the NOTCH1 interactome to expression analysis and a series of functional analyses in cell lines, patient samples and xenograft models...
September 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30209161/tp53-outperforms-other-androgen-receptor-biomarkers-to-predict-abiraterone-or-enzalutamide-outcome-in-metastatic-castration-resistant-prostate-cancer
#18
Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els G Everaert, Daan De Maeseneer, Michiel Strijbos, Alain Bols, Karen Fransis, Nick Beije, Ingeborg E de Kruijff, Valerie van Dam, Anja Brouwer, Dirk Goossens, Lien Heyrman, Gert G Van den Eynden, Annemie Rutten, Jurgen Del Favero, Mattias Rantalainen, Prabhakar Rajan, Stefan Sleijfer, Anders Ullén, Jeffrey Yachnin, Henrik Grönberg, Steven J Van Laere, Johan Lindberg, Luc Y Dirix
PURPOSE: To infer the prognostic value of simultaneous androgen receptor ( AR ) and TP53 profiling in liquid biopsies from metastatic castration-resistant prostate cancer (mCRPC) patients starting a new line of AR signalling inhibitors (ARSi). EXPERIMENTAL DESIGN: Between March 2014 and April 2017, we recruited mCRPC patients (n=168) prior to ARSi in a cohort study encompassing 10 European centres. Blood samples were collected for comprehensive profiling of CellSearch-enriched circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA)...
September 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30206165/antibody-fc-fcr-interaction-on-macrophages-as-a-mechanism-for-hyperprogressive-disease-in-non-small-cell-lung-cancer-subsequent-to-pd-1-pd-l1-blockade
#19
Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, Valeria Cancila, Mattia Boeri, Giovanni Centonze, Simona Ferro, Monica Ganzinelli, Patrizia Gasparini, Veronica Huber, Massimo Milione, Luca Porcu, Claudia Proto, Giancarlo Pruneri, Diego Signorelli, Sabina Sangaletti, Lucia Sfondrini, Chiara Storti, Elena Tassi, Alberto Bardelli, Silvia Marsoni, Valter Torri, Claudio Tripodo, Mario P Colombo, Andrea Anichini, Licia Rivoltini, Andrea Balsari, Gabriella Sozzi, Marina Garassino
PURPOSE: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI). Neither clinico-pathological features nor biological mechanisms associated with HP have been identified. EXPERIMENTAL DESIGN: Among 187 patients with non-small cell lung cancer (NSCLC) treated with ICI at our Institute, cases with HP were identified according to clinical and radiological criteria. Baseline histological samples from patients treated with ICI were evaluated by immunohistochemistry (IHC) for myeloid and lymphoid markers...
September 11, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30206164/trastuzumab-emtansine-t-dm1-in-patients-with-previously-treated-her2-overexpressing-metastatic-non-small-cell-lung-cancer-efficacy-safety-and-biomarkers
#20
Solange Peters, Rolf A Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M Kowalski, Christina S Baik, Dolores Isla, Javier de Castro Carpeño, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H Lam, Michael W Lu, Thomas E Stinchcombe
BACKGROUND: HER2-targeted therapy is not standard of care for human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer (NSCLC). This phase II study investigated efficacy and safety of the HER2-targeted antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with previously treated advanced HER2-overexpressing NSCLC. METHODS: Eligible patients had HER2-overexpressing NSCLC (centrally-tested immunohistochemistry [IHC]), and received previous platinum-based chemotherapy and targeted therapy in the case of EGFR mutation or ALK gene rearrangement...
September 11, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
journal
journal
20070
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"